Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Uncovering the Regulatory Role of miRNAs in Parkinson’s Disease: A Case Study of an Egyptian Family with a Novel Mutation
The study investigates how the mitochondrial peptidase PITRM1 mutation reshapes the miRNA landscape and contributes to the development of Parkinson’s disease (PD). It also examines how these alterations intersect with the molecular pathways implicated in Alzheimer’s disease (AD), highlighting the me...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Published: |
AUC Knowledge Fountain
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| Summary: | The study investigates how the mitochondrial peptidase PITRM1 mutation reshapes the miRNA landscape and contributes to the development of Parkinson’s disease (PD). It also examines how these alterations intersect with the molecular pathways implicated in Alzheimer’s disease (AD), highlighting the mediated cross-talk between the two diseases. Leveraging the small RNA sequencing from healthy controls, asymptomatic PITRM1 R892K carriers, and PITRM1 associated PD patients identified in an Egyptian family, the study reveals a compact but highly dysregulated miRNAs panel that segregates mutation carriers from the clinical disease. In PD vs carriers, miR‑141‑5p, miR‑205‑5p, miR‑138‑5p, miR‑885‑3p, miR‑196a‑5p, miR‑3140‑3p, and miR‑1238‑3p are strongly upregulated, whereas miR‑4422, miR‑496, and miR‑4435 are markedly downregulated. The KEGG pathway and gene ontology enrichment analysis pinpoint that the predicted and validated targets of these miRNAs are predominantly enriched in protein targeting to mitochondria, PI3K/AKT- mTOR and MAPK signaling, oxidative stress response, autophagy lysosomal flux, and broader proteostasis networks. Asymptomatic carriers display a modest and often opposite changes in specific miRNAs including; miR‑3140‑3p and miR‑1238‑3p, supporting the biphasic mechanism in which early miRNA adaptations help buffer PITRM1-dependent mitochondrial stress which eventually becomes maladaptive as damage accumulates. Integrating these findings with the current experimental literature positioned PITRM1 as the upstream driver of mitochondrial proteotoxicity and Aβ handling. PITRM1 indirectly sculpts the disease- defining miRNA network rather than being directly targeted by it. This precise association mechanistically links PD and AD at the level of mitostasis and proteostasis. Overall, the works reveals a PITRM1-related miRNA signature with potential utility as a circulating biomarker panel that stratify carriers at the risk of developing PD symptoms. It also serves as a conceptual framework miRNA guided intervention, aiming at restoring mitochondrial quality control and rebalance PI3K/AKT-mTOR and stress response pathways in PITRM1 associated and sporadic PD. |
|---|